In contrast, the FGFR3-TACC3 fusion has been described at low frequencies (2–8%) in urothelial cancers and glioblastoma and mediates it oncogenic activity through constitutive dimerization of FGFR3 driven by TACC3 [1,2,4,11,12]. This evidence concerns the gene FGFR3 and glioblastoma.